Cost-Effectiveness Analysis of Panitumumab Plus Mfolfox6 Versus Bevacizumab Plus Mfolfox6 for First-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.

Graham, C N; Hechmati, G; Hjelmgren, J; De Liège, F; Lanier, J; Knoof, A; Knox, H; Barber, B; de Pouvourville, G

Graham, C N; Hechmati, G; Hjelmgren, J; De Liège, F; Lanier, J; Knoof, A; Knox, H; Barber, B; de Pouvourville, G.

Affiliation

Graham CN; RTI Health Solutions, Research Triangle Park, NC, USA.
Hechmati G; Amgen (Europe) GmbH, Zug, Switzerland.
Hjelmgren J; Amgen (Europe) GmbH, Zug, Switzerland.
De Liège F; Amgen France SAS, Neuilly-sur-Seine, France.
Lanier J; Amgen France SAS, Neuilly-sur-Seine, France.
Knoof A; Amgen France SAS, Neuilly-sur-Seine, France.
Knox H; RTI Health Solutions, Research Triangle Park, NC, USA.
Barber B; Amgen, Inc., Thousand Oaks, CA, USA.
de Pouvourville G; ESSEC Business School, Cergy-Pontoise, France.

Value Health ; 17(7): A632, 2014 Nov.

Article in En | MEDLINE | ID: mdl-27202247

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2014 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google